

## Galenic development



### First-Generation Product

Since August 1994 preparations have been available containing fumaric acid derivatives as the active substance, that have been granted marketing authorisation by the Federal Institute for Drugs and Medical Devices (BfArM) in Germany for treatment of psoriasis. These preparations are administered in the form of enteric film-coated tablets. However there are patients in whom these tablets cause gastrointestinal symptoms, making further treatment problematic or impossible.

### Relevant Links

- [Pipeline](#)

### Second-Generation Product

For this reason another pharmaceutical form has been developed and at the same time a monosubstance has been used. This new development involves enteric-coated microtablets in capsules intended to guarantee a finer distribution in the gastrointestinal tract, in order to achieve better gastrointestinal tolerance. This has been confirmed by initial results from a pilot study. Other very positive results for the new product from the dose-finding study (Phase II) carried out in 2003 in Poland have already been presented at a conference. Additional studies (Phase III) are either in progress or are in the pipeline and we hope to be able to publish new data soon.



## Galenic development



### First-Generation Product

Since August 1994 preparations have been available containing fumaric acid derivatives as the active substance, that have been granted marketing authorisation by the Federal Institute for Drugs and Medical Devices (BfArM) in Germany for treatment of psoriasis. These preparations are administered in the form of enteric film-coated tablets. However there are patients in whom these tablets cause gastrointestinal symptoms, making further treatment problematic or impossible.

### Relevant Links

- [Pipeline](#)

### Second-Generation Product

For this reason another pharmaceutical form has been developed and at the same time a monosubstance has been used. This new development involves enteric-coated microtablets in capsules intended to guarantee a finer distribution in the gastrointestinal tract, in order to achieve better gastrointestinal tolerance. This has been confirmed by initial results from a pilot study. Other very positive results for the new product from the dose-finding study (Phase II) carried out in 2003 in Poland have already been presented at a conference. Additional studies (Phase III) are either in progress or are in the pipeline and we hope to be able to publish new data soon.

